BiomX's top three insider shareholders as of March 23, 2026 are Israel Biofund Gp Limited Partnership Orbimed (TenPercentOwner, 724.93K shares), Fibrosis Foundation Cystic (TenPercentOwner, 491.08K shares), Chidozie Ugwumba (Other, 157.74K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Israel Biofund Gp Limited Partnership Orbimed | 0 | 724,929 | 20 May, 2024 | |
| Fibrosis Foundation Cystic | 491,083 | 0 | 17 May, 2024 | |
| Chidozie Ugwumba | 0 | 157,738 | 14 Nov, 2022 | |
| James E Flynn | 0 | 65,634 | 03 Mar, 2025 | |
| Jonas Grossman | 19,617 | 0 | 17 Aug, 2021 | |
| Jonathan Eitan Solomon | Chief Executive Officer | 6,671 | 0 | 21 Apr, 2025 |
| Marina Wolfson | Chief Financial Officer | 3,608 | 0 | 21 Apr, 2025 |
| Assaf Oron | Chief Business Officer | 1,358 | 0 | 18 Sep, 2024 |
| Lynne Marie Sullivan | 658 | 0 | 30 Jul, 2021 | |
| Paul J Sekhri | 658 | 0 | 30 Jul, 2021 | |
| Alan Charles Moses | 263 | 0 | 30 Jul, 2021 | |
| Russell Greig | 0 | 197 | 30 Jul, 2021 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 16 Mar, 2026 | Reuven Yeganeh | Common Stock, $0.0001 par value per share | A | 450,000 | $2.00 | 450,000 | I | C |
| 16 Mar, 2026 | Reuven Yeganeh | Common Stock, $0.0001 par value per share | D | 450,000 | $5.00 | 0 | I | S |
| 17 Mar, 2026 | Reuven Yeganeh | Common Stock, $0.0001 par value per share | A | 530,000 | $2.00 | 530,000 | I | C |
| 17 Mar, 2026 | Reuven Yeganeh | Common Stock, $0.0001 par value per share | D | 530,000 | $5.00 | 0 | I | S |
| 16 Mar, 2026 | Reuven Yeganeh | Series Y Convertible Preferred Stock | D | 900 | $0.00 | 1,060 | I | C |
| 17 Mar, 2026 | Reuven Yeganeh | Series Y Convertible Preferred Stock | D | 1,060 | $0.00 | 0 | I | C |
| 16 Mar, 2026 | Reuven Yeganeh | Common Stock Purchase Warrants | D | 1,300,000 | $5.00 | 2,000,000 | I | S |
| 16 Mar, 2026 | Reuven Yeganeh | Common Stock Purchase Warrants | D | 2,000,000 | $5.24 | 1,700,000 | I | S |
| 16 Mar, 2026 | Reuven Yeganeh | Common Stock Purchase Warrants | D | 1,700,000 | $4.76 | 0 | I | S |
| 11 Mar, 2026 | Reuven Yeganeh | Common Stock, $0.0001 par value per share | A | 300,000 | $2.00 | 30,000 | I | C |
| 12 Mar, 2026 | Reuven Yeganeh | Common Stock, $0.0001 par value per share | D | 300,000 | $5.00 | 0 | I | S |
| 13 Mar, 2026 | Reuven Yeganeh | Common Stock, $0.0001 par value per share | A | 370,000 | $2.00 | 370,000 | I | C |
| 13 Mar, 2026 | Reuven Yeganeh | Common Stock, $0.0001 par value per share | D | 370,000 | $5.00 | 0 | I | S |
| 12 Mar, 2026 | Reuven Yeganeh | Series Y Convertible Preferred Stock | D | 600 | $0.00 | 2,700 | I | C |
| 13 Mar, 2026 | Reuven Yeganeh | Series Y Convertible Preferred Stock | D | 740 | $0.00 | 1,960 | I | C |
| 21 Apr, 2025 | James E Flynn | Warrants | A | 1,611,864 | - | 84,835 | I | A |
| 21 Apr, 2025 | James E Flynn | Warrants | A | 1,611,864 | - | 84,835 | I | A |
| 14 Apr, 2025 | Alan Charles Moses | Common Stock Options - right to Buy | A | 17,600 | $0.00 | 926 | D | A |
| 14 Apr, 2025 | Eddie Williams | Common Stock Options - right to Buy | A | 17,600 | $0.00 | 926 | D | A |
| 14 Apr, 2025 | Marina Wolfson | Common Stock | A | 68,545 | $0.00 | 3,608 | D | A |